Journal
EXPERT OPINION ON BIOLOGICAL THERAPY
Volume 9, Issue 8, Pages 1099-1106Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1517/14712590903055011
Keywords
hematopoietic stem cells; natalizumab; VLA-4
Ask authors/readers for more resources
The humanized monoclonal very late antigen 4 (VLA-4) antibody natalizumab is FDA approved for the treatment of patients with multiple sclerosis and Crohn's disease. In this review we focus on its role in the context of hematopoietic stem cell transplantation and stem cell diseases. The use of natalizumab alone or in combination with either cytotoxic drugs or other antibodies might be a new modality for stem cell mobilization and a therapeutic option for patients with hematologic malignancies.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available